Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
A
$139.19+Infinity%1D
Analyst Views on A
Wall Street analysts forecast A stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for A is 167.92 USD with a low forecast of 130.00 USD and a high forecast of 185.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast A stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for A is 167.92 USD with a low forecast of 130.00 USD and a high forecast of 185.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
4 Hold
0 Sell
Moderate Buy
Current: 140.600
Low
130.00
Averages
167.92
High
185.00
Current: 140.600
Low
130.00
Averages
167.92
High
185.00
Barclays
Equal Weight -> Overweight
upgrade
$165
2025-12-15
New
Reason
Barclays
Price Target
$165
2025-12-15
New
upgrade
Equal Weight -> Overweight
Reason
Barclays upgraded Agilent to Overweight from Equal Weight with an unchanged price target of $165. The firm adjusted ratings in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Goldman Sachs
Buy
initiated
$170
2025-12-09
Reason
Goldman Sachs
Price Target
$170
2025-12-09
initiated
Buy
Reason
Goldman Sachs initiated coverage of Agilent with a Buy rating and $170 price target. The firm rolled out coverage of the large cap life science tools stocks with the expectation that they will eventually return to their historic market growth rate of 5%. However, some end markets will recover faster than others, the analyst tells investors in a research note. Goldman is taking a more cautious view on the timing of the drug discovery end market recovery and believes the recent uptick in biotech funding is largely focused on later stage assets. It also takes a more cautious stance on U.S. academic and government spending. The firm says investors need to be selective, and likes exposure to commercialized biopharma manufacturing, later stage research, and industrials.
Morgan Stanley
initiated
$180
2025-12-02
Reason
Morgan Stanley
Price Target
$180
2025-12-02
initiated
Reason
As previously reported, Morgan Stanley initiated coverage of Agilent (A) with an Overweight rating and $180 price target. Life Science Tools and Diagnostics end market bright spots are beginning to emerge and the firm sees "plenty of catalysts" in the pipeline across its coverage, adding that it sees "lots to like in the space entering 2026." However, a recent industry valuation spike in the second half of the year leaves multiples in "a fair place," so the firm starts the group with an In-Line industry view, the analyst tells investors. Among the group, the analyst identifies Danaher (DHR) as Top Pick. This note corrects a prior version with an incorrect price target for Agilent.
Baird
Catherine Ramsey Schulte
Outperform
maintain
$142 -> $165
2025-11-25
Reason
Baird
Catherine Ramsey Schulte
Price Target
$142 -> $165
2025-11-25
maintain
Outperform
Reason
Baird analyst Catherine Ramsey Schulte raised the firm's price target on Agilent to $165 from $142 and keeps an Outperform rating on the shares. The firm updated its model following solid Q4 results which posted a revenue beat and a 2026 inline revenue outlook.
About A
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
